Zhuzhou Qianjin Pharmaceutical Co., Ltd. Class A

Zhuzhou Qianjin Pharmaceutical Co., Ltd. Class A

SSSE:600479
10.20
CNY
-0.08
(-0.78%)
0.84EPS
16.80P/E
6.10BMarket Cap
Zhuzhou Qianjin Pharmaceutical Co., Ltd. Class A
SSE:600479
(Shanghai Stock Exchange)

Recent

price

10.20

P/E

ratio

16.80

div

yld

0.04%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.68
3.44
4.33
5.39
6
6.38
6.85
7.6
7.95
8.42
8.67
8.75
9.4
8.99
8.78
8.42
7.76
Revenue per Share
0.24
0.23
0.33
0.34
0.29
0.24
0.36
0.5
0.61
0.7
0.71
0.72
0.71
0.76
0.56
0.66
0.74
Basic EPS, GAAP
-0.05
-0.11
-0.16
0.15
0.32
-0.04
0.14
0.55
0.81
0.27
1.06
0.99
1.63
0.94
0.85
0.83
- -
Free Cash Flow per Basic Share
0.3
0.21
0.17
0.22
0.17
0.17
0.13
0.17
0.25
0.4
0.5
1.03
0.58
0.35
0.37
0.35
- -
Dividend per Share
2.46
2.48
2.64
2.76
3.07
3.93
4.17
4.49
4.9
5.2
5.42
5.14
5.16
5.57
5.81
6.15
6.3
Book Value per Share
2.31
2.34
2.07
2.03
2.35
3.28
3.52
3.88
4.18
4.56
4.87
4.58
4.61
4.98
5.22
5.54
5.63
Tangible Book Value per Share
366
366
366
366
366
383
418
419
418
419
419
418
428
423
414
431
483
Basic Weighted Avg Shares
979
1,257
1,583
1,973
2,194
2,447
2,865
3,183
3,329
3,525
3,627
3,664
4,026
3,798
3,630
3,629
3,751
Sales/Revenue/Turnover
7.92
9.27
8.42
7.89
5.87
3.77
6.28
8.44
9.11
10.18
10.24
10.11
10.55
11.1
8.29
10.41
11.62
Operating Margin (%)
36
38
40
48
48
50
50
63
62
61
61
86
96
104
100
108
- -
Depreciation Expense
86
83
120
124
105
93
149
208
255
294
297
302
303
320
231
286
357
Net Income, GAAP
10.92
13.57
13.47
15.75
16.18
19.4
16
13.95
14.12
18.06
15.16
13.54
13.16
14.21
9.75
13.66
14.84
Effective Tax Rate (%)
8.82
6.59
7.59
6.27
4.79
3.8
5.22
6.53
7.67
8.35
8.19
8.24
7.51
8.44
6.36
7.89
9.51
Profit Margin (%)
594
602
505
487
685
1,266
1,296
1,495
1,643
1,854
1,781
1,689
1,816
1,973
1,396
672
700
Working Capital
1
1
1
5
32
54
47
37
27
21
62
60
45
38
26
29
24
LT Debt
940
994
1,064
1,204
1,386
1,964
2,084
2,241
2,452
2,630
2,762
2,700
2,817
3,027
3,139
3,350
3,436
Total Equity
8.85
9.46
11.7
9.97
7.69
4.3
7.78
11.37
11.92
13.57
12.66
12.84
13.16
12.84
9.4
11.34
11.89
Return on Invested Capital (%)
7.44
7.34
10.23
9.87
7.04
5.88
6.16
7.76
8.77
9.23
8.37
7.93
7.59
8.13
5.04
5.92
9.09
Return on Capital (%)
9.46
9.15
12.82
12.54
9.87
6.72
8.81
11.47
13
13.92
13.37
13.68
13.85
13.91
9.51
10.43
12.87
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
35
130
105
LT Borrowings
- -
- -
- -
LT Finance Leases
27
26
24
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
492
492
492
Market Capitalization
5,286
4,578
6,103

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,333
2,232
2,324
Cash, Cash Equivalents & STI
666
708
707
Accounts Receivable, Net
397
397
367
Inventories
487
491
518
Total Current Liabilities
1,579
1,537
1,625
Payables & Accruals
- -
- -
- -
ST Debt
35
130
105
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.53%
3.99%
6.72%
Free Cash Flow
11.44%
1.68%
1.32%
Net Income, GAAP
14.27%
0.77%
24.07%
Sales/Revenue/Turnover
4.23%
0.16%
-0.03%
Total Cash Common Dividend
17.01%
5.16%
-0.09%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,001
924
790
915
3,630
2025
1,005
813
- -
911
3,629
2026
970
948
922
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.17
0.12
0.15
0.56
2025
0.13
0.18
- -
0.22
0.66
2026
0.15
0.22
0.16
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.36
0.01
-0.01
0.37
2025
- -
- -
- -
- -
0.35
2026
- -
- -
- -
- -
- -
Business
ZhuZhou QianJin Pharmaceutical Co., Ltd. (600479.SS) researches, develops, produces and sells Chinese patent medicines, chemical medicines and feminine hygiene products in China; engages in the wholesale and retail of pharmaceuticals; and operates ancillary businesses including sales of health care products, cosmetics, disinfectants, daily necessities and equity investments. Core products encompass gynecological Qianjin tablets and capsules for women's health; blood supplementation pills and granules; valsartan capsules and enalapril maleate tablets for cardiovascular treatment; difenidol hydrochloride tablets; silybin glucamine tablets; entecavir dispersible tablets for antiviral use; finasteride tablets; ammonium benzenesulfonate tablets; and specialized gynecological wipes, spanning gynecology, pediatrics, circulatory, endocrine, digestive, nervous system and other therapeutic categories in tablets, granules and capsules. Founded in 1966 as the predecessor Zhuzhou Pharmaceutical Company's Proprietary Chinese Medicine Processing Plant, it underwent shareholding reform in 1993, listed on the Shanghai Stock Exchange in 2004 and maintains headquarters at No. 801 Zhuzhou Avenue, Tianyuan District, Zhuzhou, Hunan province, China, with primary operations across the country. In October 2025, the company completes the acquisition of 28.92% equity in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68% equity in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. for approximately CNY 620 million in cash and shares to bolster its pharmaceutical portfolio.